Mirtazapine, a common antidepressant drug used to treat depression, has shown promise in a trial published in JAMA Psychiatry. The study found that people who took it cut back their meth use, regardless of whether they had depression at the start of the study. This is a significant step forward in the treatment of meth addiction. Currently, there are no medications approved for meth dependence in the world. However, existing medications such as prescription stimulants, the anti-smoking treatment bupropion, the opioid-blocking drug naltrexone, and antidepressants may not work and may cause unnecessary side effects or safety risks. The Australian team found that mirtzapine could have the same benefit if used by doctors in community clinics. The trial also found no unexpected safety issues due to the use of these drugs.